The financial year covers the period from 1 January to 31 December 2019.
IRRAS is a global medical device company focused on delivering innovative medical solutions to improve the lives of critically ill patients. IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies. IRRAS markets and sells its comprehensive, innovative IRRAflow and Hummingbird ICP Monitoring product lines to hospitals worldwide through its direct sales organization in the United States and select European countries as well as an international network of distribution partners.
IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com.
IRRAS AB (publ) is listed on Nasdaq First North Premier Growth Market (ticker: IRRAS). Redeye AB is certified adviser of the company with email, firstname.lastname@example.org, or phone +46 8 121 576 90.
For more information, please contact:
USA Kleanthis G. Xanthopoulos, Ph.D.
President and CEO
Europe Sabina Berlin
+46 73 951 95 02 email@example.com
The information was released for public disclosure, through the agency of the contact person above, on March 20, 2020 at 4:30 p.m. (CET).
At IRRAS, your privacy and the protection of your personal data are important to us. To ensure GDPR compliance, this website does not store or track any personal information, including Google Analytics or form submission data. By using the website, you acknowledge and accept our policy.